ABVC BIOPHARMA, INC.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
Various audit, audit related and non-audit services to us is as follows:
| For the Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Audit Fees* | $155,000 | $210,000 |
| Audit Related Fees | 3,000 | 15,000 |
| Tax Fees | - | - |
| All Other Fees | - | - |
| Total Fees | $158,000 | $225,000 |
| * | The Audit Fee in 2024 includes the reaudit of our 2023 financial statements. |
|---|
Audit Fees. Audit Fees consist of fees for professional services rendered by our principal accountants for the contemporaneous audit of our annual financial statements and the review of quarterly financial statements or services that are normally provided by our principal accountants in connection with statutory and regulatory filings or engagements.
Audit Related Fees. Audit Related Fees consists of fees for assurance and related services by our principal accountants that are reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees.”
Tax Fees and All Other Fees. Tax Fees and All Other Fees Consists of fees for products and services provided by our principal accountants, other than the services reported under “Audit Fees,” “Audit-Related Fees” and “Tax Fees” above.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.